As CTLA-4 inhibitors reduce the number and function of Tregs in malignant melanoma, the positivity of FoxP3 could help in the decision-making process between monotherapy with PD-1 inhibitors and combination therapy with PD-1 and CTLA-4 inhibitors. The gene discussed is FOXP3; the disease is melanoma.